<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504139</url>
  </required_header>
  <id_info>
    <org_study_id>M-20110289</org_study_id>
    <nct_id>NCT01504139</nct_id>
  </id_info>
  <brief_title>The Luteal Phase After GnRHa Trigger - a Proof of Concept Study</brief_title>
  <official_title>The Luteal Phase After GnRHa Trigger - a Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regionshospitalet Viborg, Skive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate levels of progesterone in the luteal phase after
      various stimulations in the follicular phase and treatment with GnRH antagonist protocol
      followed by GnRHagonist as induction of ovulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate levels of progesterone in the luteal phase after
      various stimulations in the follicular phase and treatment with GnRH antagonist protocol
      followed by GnRHagonist as induction of ovulation. Furthermore the aim is to explore whether
      the luteal phase can be supported with small daily boluses of hCG without the administration
      of exogenous P, while maintaining good reproductive outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of progesterone in the mid-luteal phase.</measure>
    <time_frame>up to 1-1Â½years.</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Progesterone Levels</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>hCG in the late follicular phase + luteal phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hCG in the follicular phase + luteal phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LH in the luteal phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal progesterone and estradiol in the luteal phase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase</intervention_name>
    <description>when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).</description>
    <arm_group_label>hCG in the late follicular phase + luteal phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase</intervention_name>
    <description>hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.</description>
    <arm_group_label>hCG in the follicular phase + luteal phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase</intervention_name>
    <description>LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.</description>
    <arm_group_label>LH in the luteal phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase</intervention_name>
    <description>The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-</description>
    <arm_group_label>vaginal progesterone and estradiol in the luteal phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women from the age of 25 up to 40

          -  Serum-FSH and serum-LH levels under 12 IU/L

          -  Length of period between 25 and 34 days

          -  BMI between 18 and 30

        Exclusion Criteria:

          -  less than 2 ovaries

          -  uterine abnormalities

          -  PCOS or UL-PCO (more than 11 follicles over 12 mm in 1 ovary
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helle Olesen Elbaek</last_name>
    <role>Study Director</role>
    <affiliation>The Fertility Clinic, Skive Regional Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Fertility clinic, Regional Hospital Skive</name>
      <address>
        <city>Skive</city>
        <state>Central Jutland</state>
        <zip>7800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Helle Olesen Elbaek</investigator_full_name>
    <investigator_title>Clinical Director, M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

